Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Woodcock Bemoans Lack Of 'Biobetter' Provision In BPCIA

Oct 03 2019

• By Michael Cipriano

Woodcock_Janet_1200x675 — CDER Director Janet Woodcock discussed the future of the US biosimilars market.

Related Content

Biosimilars In EU: From 'New Mess' To Beacon For Safety

Jun 26 2017

Avoiding ‘Groundhog Day’: US FDA’s Biosimilar Action Plan Applies Lessons From Generic Competition

Jul 23 2018

Best Pathway To Interchangeable Insulins Is In The Eye Of The Beholder

May 15 2019

Gottlieb Shifts From Regulatory To Reimbursement Focus In One Of First Post-Commissioner Appearances

May 13 2019

Gottlieb Calls On Congress To Act On US Biosimilars Uptake

Aug 27 2019

Additional Topics

United States Biologics Biosimilars Research & Development Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window